CN107389932B - 用于从含纤维蛋白原的样品中分离目标分子或颗粒的方法 - Google Patents
用于从含纤维蛋白原的样品中分离目标分子或颗粒的方法 Download PDFInfo
- Publication number
- CN107389932B CN107389932B CN201710338814.XA CN201710338814A CN107389932B CN 107389932 B CN107389932 B CN 107389932B CN 201710338814 A CN201710338814 A CN 201710338814A CN 107389932 B CN107389932 B CN 107389932B
- Authority
- CN
- China
- Prior art keywords
- fibrinogen
- fibrin
- sample
- particle
- fibrin ferment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108010049003 Fibrinogen Proteins 0.000 title claims abstract description 173
- 102000008946 Fibrinogen Human genes 0.000 title claims abstract description 173
- 229940012952 fibrinogen Drugs 0.000 title claims abstract description 173
- 239000002245 particle Substances 0.000 title claims abstract description 104
- 238000000034 method Methods 0.000 title abstract description 105
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims abstract description 213
- 108010073385 Fibrin Proteins 0.000 claims abstract description 203
- 102000009123 Fibrin Human genes 0.000 claims abstract description 203
- 229950003499 fibrin Drugs 0.000 claims abstract description 203
- 210000004369 blood Anatomy 0.000 claims description 103
- 239000008280 blood Substances 0.000 claims description 103
- 239000000835 fiber Substances 0.000 claims description 49
- 241000894006 Bacteria Species 0.000 claims description 33
- 210000001772 blood platelet Anatomy 0.000 claims description 31
- 239000000126 substance Substances 0.000 claims description 31
- 239000000203 mixture Substances 0.000 claims description 27
- 239000006249 magnetic particle Substances 0.000 claims description 23
- 238000000926 separation method Methods 0.000 claims description 23
- 150000007523 nucleic acids Chemical class 0.000 claims description 22
- 239000003153 chemical reaction reagent Substances 0.000 claims description 21
- 108020004707 nucleic acids Proteins 0.000 claims description 19
- 102000039446 nucleic acids Human genes 0.000 claims description 19
- 239000000654 additive Substances 0.000 claims description 17
- 230000000996 additive effect Effects 0.000 claims description 17
- 230000027455 binding Effects 0.000 claims description 17
- 238000009472 formulation Methods 0.000 claims description 17
- 102000004190 Enzymes Human genes 0.000 claims description 16
- 108090000790 Enzymes Proteins 0.000 claims description 16
- 229940088598 enzyme Drugs 0.000 claims description 16
- 101000772006 Bombus ignitus Venom serine protease Bi-VSP Proteins 0.000 claims description 15
- 108010071289 Factor XIII Proteins 0.000 claims description 15
- 229940012444 factor xiii Drugs 0.000 claims description 15
- 239000012530 fluid Substances 0.000 claims description 14
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 12
- 239000011575 calcium Substances 0.000 claims description 12
- 229910052791 calcium Inorganic materials 0.000 claims description 12
- 102000037865 fusion proteins Human genes 0.000 claims description 12
- 108020001507 fusion proteins Proteins 0.000 claims description 12
- 241000700605 Viruses Species 0.000 claims description 11
- 210000004027 cell Anatomy 0.000 claims description 11
- 239000013592 cell lysate Substances 0.000 claims description 10
- 230000001580 bacterial effect Effects 0.000 claims description 7
- 239000002738 chelating agent Substances 0.000 claims description 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 7
- 238000005215 recombination Methods 0.000 claims description 7
- 230000006798 recombination Effects 0.000 claims description 7
- 241000233866 Fungi Species 0.000 claims description 6
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 6
- 230000004913 activation Effects 0.000 claims description 5
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 claims description 4
- 102000002322 Egg Proteins Human genes 0.000 claims description 4
- 108010000912 Egg Proteins Proteins 0.000 claims description 4
- 235000014103 egg white Nutrition 0.000 claims description 4
- 210000000969 egg white Anatomy 0.000 claims description 4
- 230000023555 blood coagulation Effects 0.000 claims description 3
- 230000008859 change Effects 0.000 claims description 2
- 238000006243 chemical reaction Methods 0.000 abstract description 8
- 210000002950 fibroblast Anatomy 0.000 abstract description 8
- 239000000523 sample Substances 0.000 description 255
- 238000001514 detection method Methods 0.000 description 33
- 239000011324 bead Substances 0.000 description 23
- 241000191967 Staphylococcus aureus Species 0.000 description 22
- 244000005700 microbiome Species 0.000 description 18
- PXFBZOLANLWPMH-UHFFFAOYSA-N 16-Epiaffinine Natural products C1C(C2=CC=CC=C2N2)=C2C(=O)CC2C(=CC)CN(C)C1C2CO PXFBZOLANLWPMH-UHFFFAOYSA-N 0.000 description 13
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 13
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 13
- 239000003114 blood coagulation factor Substances 0.000 description 13
- 238000002360 preparation method Methods 0.000 description 12
- 230000015572 biosynthetic process Effects 0.000 description 11
- 239000000306 component Substances 0.000 description 10
- 230000008569 process Effects 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- 210000002966 serum Anatomy 0.000 description 10
- 206010040047 Sepsis Diseases 0.000 description 9
- 239000000872 buffer Substances 0.000 description 9
- 230000015556 catabolic process Effects 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 9
- 238000006731 degradation reaction Methods 0.000 description 9
- 102000005525 fibrillarin Human genes 0.000 description 8
- 208000015181 infectious disease Diseases 0.000 description 8
- 230000003993 interaction Effects 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 210000004623 platelet-rich plasma Anatomy 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 208000013223 septicemia Diseases 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 7
- 230000008901 benefit Effects 0.000 description 7
- 102000023732 binding proteins Human genes 0.000 description 7
- 108091008324 binding proteins Proteins 0.000 description 7
- 108020002231 fibrillarin Proteins 0.000 description 7
- 239000004615 ingredient Substances 0.000 description 7
- 238000012545 processing Methods 0.000 description 7
- -1 specific antibody Proteins 0.000 description 7
- 108090000190 Thrombin Proteins 0.000 description 6
- 239000003633 blood substitute Substances 0.000 description 6
- 238000010586 diagram Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 239000012678 infectious agent Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 229960004072 thrombin Drugs 0.000 description 6
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 5
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 5
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 5
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 5
- 239000012472 biological sample Substances 0.000 description 5
- 230000015271 coagulation Effects 0.000 description 5
- 238000005345 coagulation Methods 0.000 description 5
- 239000012141 concentrate Substances 0.000 description 5
- 238000003745 diagnosis Methods 0.000 description 5
- 235000013601 eggs Nutrition 0.000 description 5
- 230000035945 sensitivity Effects 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 229960000187 tissue plasminogen activator Drugs 0.000 description 5
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 4
- XTWYTFMLZFPYCI-UHFFFAOYSA-N Adenosine diphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O XTWYTFMLZFPYCI-UHFFFAOYSA-N 0.000 description 4
- 241000588919 Citrobacter freundii Species 0.000 description 4
- 108010088842 Fibrinolysin Proteins 0.000 description 4
- 238000009833 condensation Methods 0.000 description 4
- 230000005494 condensation Effects 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 210000002381 plasma Anatomy 0.000 description 4
- 238000006116 polymerization reaction Methods 0.000 description 4
- 238000005464 sample preparation method Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 239000003053 toxin Substances 0.000 description 4
- 231100000765 toxin Toxicity 0.000 description 4
- 108091023037 Aptamer Proteins 0.000 description 3
- 108010067306 Fibronectins Proteins 0.000 description 3
- 102000016359 Fibronectins Human genes 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 241001494479 Pecora Species 0.000 description 3
- 102000013566 Plasminogen Human genes 0.000 description 3
- 108010051456 Plasminogen Proteins 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 238000004166 bioassay Methods 0.000 description 3
- 239000003914 blood derivative Substances 0.000 description 3
- 210000003850 cellular structure Anatomy 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000004132 cross linking Methods 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 229940001501 fibrinolysin Drugs 0.000 description 3
- 230000001951 hemoperfusion Effects 0.000 description 3
- 230000003301 hydrolyzing effect Effects 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 238000003752 polymerase chain reaction Methods 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000004064 recycling Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- 235000005979 Citrus limon Nutrition 0.000 description 2
- 244000131522 Citrus pyriformis Species 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 108010067770 Endopeptidase K Proteins 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 108010000196 Factor XIIIa Proteins 0.000 description 2
- 108010034145 Helminth Proteins Proteins 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- 206010051125 Hypofibrinogenaemia Diseases 0.000 description 2
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 2
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 101710163270 Nuclease Proteins 0.000 description 2
- 238000001069 Raman spectroscopy Methods 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241000191940 Staphylococcus Species 0.000 description 2
- 108060008539 Transglutaminase Proteins 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 239000012491 analyte Substances 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 239000000090 biomarker Substances 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 238000009640 blood culture Methods 0.000 description 2
- 230000000157 blood function Effects 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 229910001424 calcium ion Inorganic materials 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 230000007515 enzymatic degradation Effects 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- 244000000013 helminth Species 0.000 description 2
- 108010037896 heparin-binding hemagglutinin Proteins 0.000 description 2
- 229940106780 human fibrinogen Drugs 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 239000006101 laboratory sample Substances 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000004088 simulation Methods 0.000 description 2
- 239000003998 snake venom Substances 0.000 description 2
- 239000013076 target substance Substances 0.000 description 2
- 239000003634 thrombocyte concentrate Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 102000003601 transglutaminase Human genes 0.000 description 2
- FFRBMBIXVSCUFS-UHFFFAOYSA-N 2,4-dinitro-1-naphthol Chemical compound C1=CC=C2C(O)=C([N+]([O-])=O)C=C([N+]([O-])=O)C2=C1 FFRBMBIXVSCUFS-UHFFFAOYSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 241000304886 Bacilli Species 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 241000588923 Citrobacter Species 0.000 description 1
- 241001478240 Coccus Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000194033 Enterococcus Species 0.000 description 1
- 108010014173 Factor X Proteins 0.000 description 1
- 101710145505 Fiber protein Proteins 0.000 description 1
- 206010016590 Fibrin deposition on lens postoperative Diseases 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108010059712 Pronase Proteins 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 238000002829 antibacterial sensitivity test Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 231100000693 bioaccumulation Toxicity 0.000 description 1
- 239000006161 blood agar Substances 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 229960000182 blood factors Drugs 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- 208000037815 bloodstream infection Diseases 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000003715 calcium chelating agent Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 229940043430 calcium compound Drugs 0.000 description 1
- 150000001674 calcium compounds Chemical class 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000003196 chaotropic effect Effects 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical group OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000000701 coagulant Substances 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 108010037721 cytase Proteins 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 108010073651 fibrinmonomer Proteins 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000000383 hazardous chemical Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 238000013095 identification testing Methods 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 229920002113 octoxynol Polymers 0.000 description 1
- 230000024241 parasitism Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 229940012957 plasmin Drugs 0.000 description 1
- 230000010118 platelet activation Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 230000031915 positive regulation of coagulation Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 238000009790 rate-determining step (RDS) Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 239000012744 reinforcing agent Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000002345 thrombinlike Effects 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 239000000304 virulence factor Substances 0.000 description 1
- 230000007923 virulence factor Effects 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
- C12Q1/14—Streptococcus; Staphylococcus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/56—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving blood clotting factors, e.g. involving thrombin, thromboplastin, fibrinogen
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
- G01N33/56938—Staphylococcus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/745—Assays involving non-enzymic blood coagulation factors
- G01N2333/75—Fibrin; Fibrinogen
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/974—Thrombin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Neurosurgery (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Sampling And Sample Adjustment (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH01478/10 | 2010-09-15 | ||
| CH14782010 | 2010-09-15 | ||
| CH20412010 | 2010-12-07 | ||
| CH02041/10 | 2010-12-07 | ||
| CH01207/11 | 2011-07-20 | ||
| CH12072011 | 2011-07-20 | ||
| CN201180044211.XA CN103108959B (zh) | 2010-09-15 | 2011-09-15 | 用于从包括成分血的含纤维蛋白原的样品中分离目标分子或颗粒的方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201180044211.XA Division CN103108959B (zh) | 2010-09-15 | 2011-09-15 | 用于从包括成分血的含纤维蛋白原的样品中分离目标分子或颗粒的方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN107389932A CN107389932A (zh) | 2017-11-24 |
| CN107389932B true CN107389932B (zh) | 2019-11-22 |
Family
ID=45044632
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710338814.XA Active CN107389932B (zh) | 2010-09-15 | 2011-09-15 | 用于从含纤维蛋白原的样品中分离目标分子或颗粒的方法 |
| CN201180044211.XA Active CN103108959B (zh) | 2010-09-15 | 2011-09-15 | 用于从包括成分血的含纤维蛋白原的样品中分离目标分子或颗粒的方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201180044211.XA Active CN103108959B (zh) | 2010-09-15 | 2011-09-15 | 用于从包括成分血的含纤维蛋白原的样品中分离目标分子或颗粒的方法 |
Country Status (17)
| Country | Link |
|---|---|
| US (4) | US9689881B2 (enExample) |
| EP (2) | EP2616550B1 (enExample) |
| JP (1) | JP5999776B2 (enExample) |
| KR (1) | KR101948944B1 (enExample) |
| CN (2) | CN107389932B (enExample) |
| AU (2) | AU2011303467C1 (enExample) |
| CA (1) | CA2811493C (enExample) |
| CY (1) | CY1122166T1 (enExample) |
| DK (2) | DK2616550T3 (enExample) |
| ES (2) | ES2751660T3 (enExample) |
| HR (1) | HRP20191785T1 (enExample) |
| HU (2) | HUE028915T2 (enExample) |
| LT (1) | LT3067431T (enExample) |
| PL (2) | PL2616550T3 (enExample) |
| PT (1) | PT3067431T (enExample) |
| SI (1) | SI3067431T1 (enExample) |
| WO (1) | WO2012035508A2 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9689881B2 (en) | 2010-09-15 | 2017-06-27 | Spinomix S.A. | Method for separating target molecules or particles from fibrinogen-containing samples including blood components |
| CN103702674B (zh) | 2011-06-27 | 2018-05-29 | 爱默蕾大学 | 血小板裂解物的组合物、用途和制备 |
| EP2979093B1 (en) * | 2013-03-29 | 2019-10-23 | Siemens Healthcare Diagnostics Inc. | Rare cell concentration |
| ES2740838T3 (es) * | 2014-06-01 | 2020-02-06 | Debiopharm Int Sa | Dispositivo de recolección y procesamiento de muestras |
| US12397302B2 (en) | 2015-11-30 | 2025-08-26 | Dh Technologies Development Pte. Ltd. | Electromagnetic assemblies for processing fluids |
| WO2017156375A1 (en) | 2016-03-10 | 2017-09-14 | Arthrex, Inc. | Systems and methods for preparing a thrombin serum |
| WO2017156379A2 (en) | 2016-03-10 | 2017-09-14 | Arthrex, Inc. | Systems and methods for preparing protein enhanced serums |
| KR20210052389A (ko) | 2018-08-27 | 2021-05-10 | 리제너론 파마슈티칼스 인코포레이티드 | 다운스트림 정제에서의 라만 분광법의 사용 |
| JP7298449B2 (ja) * | 2019-11-14 | 2023-06-27 | 株式会社島津製作所 | 血液凝固分析装置、及び分注ノズルの洗浄方法 |
Citations (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2281768A1 (fr) * | 1974-08-12 | 1976-03-12 | Baxter Laboratories Inc | Tube de collecte et de traitement de liquides biologiques |
| EP0325106A1 (de) * | 1988-01-05 | 1989-07-26 | Axel Dr. Linhart | Verfahren und Test-Kit zur semiquantitativen Bestimmung des Kalziumgehaltes im Blut |
| EP0587398A1 (en) * | 1992-09-09 | 1994-03-16 | Tokuyama Corporation | Method of assaying fibrinogen, dry reagent therefor, and process for the preparation thereof |
| WO1994028168A1 (en) * | 1993-05-28 | 1994-12-08 | Cardiovascular Diagnostics, Inc. | Improved method and analytical system for performing fibrinogen assays accurately, rapidly and simply |
| CN1246069A (zh) * | 1997-01-31 | 2000-03-01 | 奥姆里克斯生物化学品公司 | 一种含纤维蛋白原的稳定化混合物 |
| JP2000262499A (ja) * | 2000-01-01 | 2000-09-26 | Terumo Corp | 採血管 |
| JP3292760B2 (ja) * | 1993-04-22 | 2002-06-17 | テルモ株式会社 | 採血管およびその製造方法 |
| WO2005021799A2 (en) * | 2003-08-15 | 2005-03-10 | University Of South Florida | Materials and methods for capture of pathogens and removal of aurintricarboxylic acid from a sample |
| CN1606447A (zh) * | 2001-10-03 | 2005-04-13 | 克里斯托弗·J·伍尔弗顿 | 保存稳定的纤维蛋白原溶液 |
| WO2007089948A2 (en) * | 2006-02-01 | 2007-08-09 | Spinal Restoration, Inc. | Improved apparatus and method for injection of fibrin sealant in spinal applications |
| WO2010004004A1 (en) * | 2008-07-09 | 2010-01-14 | Profibrix Bv | Recombinant fibrinogen |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2625321B1 (fr) * | 1987-12-24 | 1992-10-02 | Pasteur Institut | Reactif pour le diagnostic de staphylococcus aureus par agglutination |
| DE3803463A1 (de) * | 1988-02-05 | 1989-08-17 | Linhart Axel | Semiquantitativer kalzium-schnelltest |
| US5691160A (en) * | 1992-08-14 | 1997-11-25 | Biogen, Inc. | Effects of actin filaments of fibrin clot structure and lysis |
| WO1995015397A1 (en) | 1993-12-03 | 1995-06-08 | Dorn Gordon L | Method for improving quantitative recovery of microorganisms fro m specimens containing blood components |
| DE19602673A1 (de) * | 1996-01-25 | 1997-08-07 | Pereg Gmbh | Synthetische Testanschmutzung |
| US6680195B1 (en) * | 1997-11-26 | 2004-01-20 | Inhibitex, Inc. | Extracellular matrix-binding proteins from staphylococcus aureus |
| US6686204B2 (en) * | 2001-08-27 | 2004-02-03 | Becton, Dickinson & Company | Collection device |
| JP4718833B2 (ja) * | 2002-05-01 | 2011-07-06 | シナプス ベスローテン フェンノートシャップ | 複合生物媒体における、一時的なタンパク質分解活性の濃度を決定するための診断試験 |
| EP1400589B1 (de) | 2002-09-18 | 2006-08-09 | SIRS-Lab GmbH | Verfahren zum Nachweis prokaryontischer DNA |
| US20050065454A1 (en) * | 2003-09-22 | 2005-03-24 | Becton, Dickinson And Company | Non-evacuated blood collection tube |
| US7399609B2 (en) * | 2003-12-30 | 2008-07-15 | 3M Innovative Properties Company | Staphylococcus detection |
| DE102005009479A1 (de) | 2005-03-02 | 2006-09-07 | Molzym Gmbh & Co. Kg | Verwendung von Nukleasen zum Abbau von Nukleinsäure in Gegenwart von chaotropen Agenzien und/oder Tensiden |
| US20100009409A1 (en) * | 2005-07-29 | 2010-01-14 | Ecole Polytechnique Federale De Lausanne | Molecular variant fibrinogen fusion proteins |
| US20080299587A1 (en) * | 2007-05-03 | 2008-12-04 | Dennis Durbin | Methods of measuring inhibition of platelet aggregation by thrombin receptor antagonists |
| CA2693565C (en) | 2007-08-02 | 2015-05-26 | Universite Laval | Concentration and enrichment of microbial cells and microbial nucleic acids from bodily fluids |
| JP5029217B2 (ja) * | 2007-08-27 | 2012-09-19 | 東レ株式会社 | シート状物の製造方法 |
| CA2768485C (en) | 2009-07-16 | 2018-12-04 | Timothy Foster | Treatment of staphylococci infections using recombinant fibrinogen binding protein clumping factor a |
| US9689881B2 (en) | 2010-09-15 | 2017-06-27 | Spinomix S.A. | Method for separating target molecules or particles from fibrinogen-containing samples including blood components |
-
2011
- 2011-09-15 US US13/822,209 patent/US9689881B2/en active Active
- 2011-09-15 CA CA2811493A patent/CA2811493C/en active Active
- 2011-09-15 EP EP11788227.4A patent/EP2616550B1/en active Active
- 2011-09-15 AU AU2011303467A patent/AU2011303467C1/en active Active
- 2011-09-15 DK DK11788227.4T patent/DK2616550T3/en active
- 2011-09-15 CN CN201710338814.XA patent/CN107389932B/zh active Active
- 2011-09-15 JP JP2013528815A patent/JP5999776B2/ja active Active
- 2011-09-15 KR KR1020137009329A patent/KR101948944B1/ko active Active
- 2011-09-15 LT LT16154770T patent/LT3067431T/lt unknown
- 2011-09-15 DK DK16154770.8T patent/DK3067431T3/da active
- 2011-09-15 HU HUE11788227A patent/HUE028915T2/en unknown
- 2011-09-15 CN CN201180044211.XA patent/CN103108959B/zh active Active
- 2011-09-15 ES ES16154770T patent/ES2751660T3/es active Active
- 2011-09-15 PL PL11788227T patent/PL2616550T3/pl unknown
- 2011-09-15 PL PL16154770T patent/PL3067431T3/pl unknown
- 2011-09-15 SI SI201131797T patent/SI3067431T1/sl unknown
- 2011-09-15 EP EP16154770.8A patent/EP3067431B1/en active Active
- 2011-09-15 ES ES11788227T patent/ES2571127T3/es active Active
- 2011-09-15 HU HUE16154770A patent/HUE045771T2/hu unknown
- 2011-09-15 PT PT161547708T patent/PT3067431T/pt unknown
- 2011-09-15 WO PCT/IB2011/054035 patent/WO2012035508A2/en not_active Ceased
-
2016
- 2016-12-02 AU AU2016266066A patent/AU2016266066B2/en active Active
-
2017
- 2017-05-22 US US15/601,677 patent/US20170336424A1/en not_active Abandoned
-
2019
- 2019-10-02 HR HRP20191785TT patent/HRP20191785T1/hr unknown
- 2019-10-11 CY CY20191101074T patent/CY1122166T1/el unknown
-
2021
- 2021-01-28 US US17/160,814 patent/US20210148940A1/en not_active Abandoned
-
2023
- 2023-08-09 US US18/231,880 patent/US20240280593A1/en not_active Abandoned
Patent Citations (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2281768A1 (fr) * | 1974-08-12 | 1976-03-12 | Baxter Laboratories Inc | Tube de collecte et de traitement de liquides biologiques |
| EP0325106A1 (de) * | 1988-01-05 | 1989-07-26 | Axel Dr. Linhart | Verfahren und Test-Kit zur semiquantitativen Bestimmung des Kalziumgehaltes im Blut |
| EP0587398A1 (en) * | 1992-09-09 | 1994-03-16 | Tokuyama Corporation | Method of assaying fibrinogen, dry reagent therefor, and process for the preparation thereof |
| JP3292760B2 (ja) * | 1993-04-22 | 2002-06-17 | テルモ株式会社 | 採血管およびその製造方法 |
| WO1994028168A1 (en) * | 1993-05-28 | 1994-12-08 | Cardiovascular Diagnostics, Inc. | Improved method and analytical system for performing fibrinogen assays accurately, rapidly and simply |
| CN1246069A (zh) * | 1997-01-31 | 2000-03-01 | 奥姆里克斯生物化学品公司 | 一种含纤维蛋白原的稳定化混合物 |
| JP2000262499A (ja) * | 2000-01-01 | 2000-09-26 | Terumo Corp | 採血管 |
| CN1606447A (zh) * | 2001-10-03 | 2005-04-13 | 克里斯托弗·J·伍尔弗顿 | 保存稳定的纤维蛋白原溶液 |
| WO2005021799A2 (en) * | 2003-08-15 | 2005-03-10 | University Of South Florida | Materials and methods for capture of pathogens and removal of aurintricarboxylic acid from a sample |
| WO2007089948A2 (en) * | 2006-02-01 | 2007-08-09 | Spinal Restoration, Inc. | Improved apparatus and method for injection of fibrin sealant in spinal applications |
| WO2010004004A1 (en) * | 2008-07-09 | 2010-01-14 | Profibrix Bv | Recombinant fibrinogen |
Non-Patent Citations (3)
| Title |
|---|
| Blood Clotting in Limulus Immunity:Physiological Impairment of Clot-Entrapped Bacteria;Peter A. Bosniak等;《Biol. Bull.》;20041031;全文 * |
| In situ formation, manipulation, and imaging of droplet-encapsulated fibrin networks;Heather M. Evans等;《Lab Chip》;20090330;全文 * |
| 人凝血酶及纤维蛋白原的制备;程文康;《中国优秀硕士学位论文全文数据库 工程科技I辑》;20041215;全文 * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107389932B (zh) | 用于从含纤维蛋白原的样品中分离目标分子或颗粒的方法 | |
| AU2021236442B2 (en) | Methods and systems for rapid detection of microorganisms using recombinant bacteriophage | |
| DK2643475T3 (en) | Analysis of Direct Factor Xa Inhibitors | |
| JP2021516964A (ja) | 微生物検出タンパク質を使用して微生物を検出するための方法および細胞結合構成要素の他の用途 | |
| EP2723886B1 (en) | Determination of direct thrombin inhibitors in serum or urine | |
| Hellwig et al. | Detection, isolation and characterization of phage-host complexes using BONCAT and click chemistry | |
| HK1247280B (zh) | 用於从含纤维蛋白原的样品中分离目标分子或颗粒的方法 | |
| EP2682749A1 (en) | Method for detecting analyte, and measuring kit | |
| DE102009021681A1 (de) | Staphylococcus aureus bindende Peptide, deren Verwendung und Verfahren und Kits zur Anreicherung, Immobilisierung und zum Nachweis von Staphylococcus aureus | |
| TW202134653A (zh) | 以重組內孢子或細菌作為感測元件以偵測化合物、抗體或蛋白質之方法 | |
| KR102326232B1 (ko) | 그람 음성균 검출 시스템 및 이를 이용한 검출 방법 | |
| US20250290118A1 (en) | Rapid antibiotic susceptibility test and identification method | |
| WO2023114982A1 (en) | Microbe agglutination method and reagents | |
| Xu et al. | Separation and detection of Gram-negative bacteria via vancomycin-functionalized magnetic beads and aminopeptidase test strips |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1247280 Country of ref document: HK |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant |